<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595215</url>
  </required_header>
  <id_info>
    <org_study_id>CRD-12-1076</org_study_id>
    <nct_id>NCT03595215</nct_id>
  </id_info>
  <brief_title>Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home</brief_title>
  <acronym>OAB Aim 2</acronym>
  <official_title>Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranova, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Theranova, L.L.C.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical study, which focuses on feasibility and proof-of-principle, will be
      conducted in 11 female subjects (55-100 years old) with UI. Subjects will use the device
      three times a week for 8 weeks and complete 3-day &quot;voiding diaries&quot; to record instances of UI
      episodes and OAB quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">July 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urge Incontinence Episodes</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Micturitions Per Day</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QoL)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Improvement in incontinence QoL scores compared to pre-treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>TENS Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TENS</intervention_name>
    <description>Transcutaneous electrical nerve stimulation</description>
    <arm_group_label>TENS Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females

          2. 55-100 years old

          3. Have an average urinary frequency of ≥ 8 voids per 24 hours (based on a pre-treatment
             3-day voiding &quot;training&quot; diary)

          4. Have self-reported bladder symptoms of more than 3 months

          5. Are ambulatory and able to use the toilet independently

          6. Have been off antimuscarinics, anticholinergics or beta-3 agonists for at least 2
             weeks prior to enrollment OR on a stable dose for the prior 3 months

          7. Patient has urinary urge incontinence of ≥ 8 episodes from a 3-day diary (with
             incontinence associated at urge level moderate or severe)

          8. Able to provide informed consent

          9. Capable and willing to follow all study-related procedures

        Exclusion Criteria:

          1. Have primary complaint of stress urinary incontinence

          2. Have a pacemaker or implantable defibrillator

          3. Had botox injections in the bladder or pelvic floor muscles in the past 12 months

          4. Have a current urinary tract or vaginal infection

          5. Have an active implantable SNS device (InterStim &amp; Bion)

          6. Have been diagnosed with peripheral neuropathy or nerve damage

          7. Currently pregnant

          8. Deemed unsuitable for enrollment in study by the investigator based on subjects'
             history or physical examination
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <results_first_submitted>November 13, 2019</results_first_submitted>
  <results_first_submitted_qc>December 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2020</results_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TENS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03595215/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TENS Treatment Arm</title>
          <description>This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
TENS: Transcutaneous electrical nerve stimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TENS Treatment Arm</title>
          <description>This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
TENS: Transcutaneous electrical nerve stimulation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UUI</title>
          <description>Urge Incontinence Episodes</description>
          <units>Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urge Incontinence Episodes</title>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TENS Treatment Arm</title>
            <description>This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
TENS: Transcutaneous electrical nerve stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urge Incontinence Episodes</title>
          <units>UUI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Micturitions Per Day</title>
        <time_frame>Baseline and 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life (QoL)</title>
        <description>Improvement in incontinence QoL scores compared to pre-treatment</description>
        <time_frame>Baseline and 8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 8 weeks for each for each participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TENS Treatment Arm</title>
          <description>This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
TENS: Transcutaneous electrical nerve stimulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Associate</name_or_title>
      <organization>TheraNova</organization>
      <phone>415-926-8616</phone>
      <email>akrajcevska@theranova.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

